Skip to main content
Equibles
INDV logo

INDV · Indivior Pharmaceuticals, Inc.

Track INDV — free

Use INDV with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about INDV

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$39.06 -0.37 (-0.94%) At close · Aug 19
Market Cap
$4.61B
Shares
118.01M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$39.43 Open$39.48 Day$39.08–39.92 52W close$22.51–41.83 Avg vol 30d2.1M Short int10.9M · 9.2% float · 7.1d Short vol64% Last earningsAug 3, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 3

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 3, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Strong Sentiment Very Bullish Fundamentals Strong Quant / Vol Moderate
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +12%
      above
      Price vs 50-day avg −0%
      below
      RSI (14) 52
      neutral
      MACD trend Positive
      52-week position 88%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return −3%
      trailing
      6-month return +17%
      trailing
      YTD return +10%
      this year
      Relative strength +7%
      vs S&P · 6-mo
      Sentiment
      smart money
      Very Bullish
      Trend (MA cross) No cross
      50d $40 › 200d $35 — 50d above 200d
      Institutional flow Accumulating
      +15% holders QoQ · +89 funds added
      Insider flow Accumulating
      Net +$54.4K over 90 days · 0% sells
      Short interest Falling
      9.22% of float · ▼ -3.5% MoM · 7.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      334 holders — near 1-yr high, broad support
      Squeeze score 74
      high risk · 0–100
      Fundamentals
      Strong
      Revenue growth +4%
      Y/Y
      Gross margin 80%
      contracting
      EPS growth +3180%
      Y/Y
      Free cash flow $-93.0M
      Valuation P/E 14
      below peers
      Buyback $100.0M
      remaining
      Balance sheet $124.0M
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 37%
      annualized · 1-yr
      Max drawdown −21%
      past year
      ATR 3.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 2
      Latest guidance · from the 8-K filed Aug 3, 2026
      Full-year 2026
      Adjusted EBITDA Non-GAAP Initiated $700M – $740M
      2026
      Non-GAAP operating expenses Non-GAAP up to $450M
      Cash flow from operations $420M
      Prior guidance period ended · from the 8-K filed Oct 30, 2025
      Non-GAAP SG&A · FY 2025 $510M – $520M
      Adjusted EBITDA · FY 2025 $400M – $420M
      Non-GAAP R&D · FY 2025 $75M – $80M
      Total Net Revenue · FY 2025 $1.18B – $1.22B
      SUBLOCADE Net Revenue · FY 2025 $825M – $845M
      Non-GAAP Operating Expenses · FY 2025 $585M – $600M
      Guided vs delivered · last 2 settled
      Total Net Revenue FY 2025
      guided $1.18B – $1.22B
      $1.24B Beat +3.3%
      Total company full-year 2023 net revenue full-year 2023
      guided $1.03B – $1.09B
      $1.09B Beat +3.1%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +12% Bullish
      Price vs 50-day avg
      −0% Neutral
      RSI (14)
      52 Neutral
      MACD trend
      Positive Bullish
      52-week position
      88% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 4 of 6
      Trend (MA cross) No cross
      50d $40 › 200d $35 — 50d above 200d
      Institutional flow Accumulating
      +15% holders QoQ · +89 funds added
      Insider flow Accumulating
      Net +$54.4K over 90 days · 0% sells
      Short interest Falling
      9.22% of float · ▼ -3.5% MoM · 7.1 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      334 holders — near 1-yr high, broad support
      Price context
      position in its 52-week range
      Range low $23 Now $39 · 88% Range high $42
      vs 200-day avg +12% vs 50-day avg 0%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adj. EBITDA Margin non-GAAP 54% Q2 2026 —
      Adjusted EBITDA non-GAAP $350M Six Months Ended June 30, 2026 —
      Average share repurchase price $37.52 Q2 2026 —
      Convertible senior notes issued $500M 2026 —
      CRM enrollments per month 1,300 Q2 2026 —
      dispense unit volume growth 18% Q2 2026 —
      Growth in new patient starts 27% Q2 2026 vs Q2 2025 —
      HCPs with 5+ SUBLOCADE Patients growth (YoY) 18% Q2 2026 —
      Non-GAAP diluted earnings per share non-GAAP $2.1 Six Months Ended June 30, 2026 —
      Non-GAAP net income non-GAAP $266M Six Months Ended June 30, 2026 —
      Non-GAAP operating expenses non-GAAP $229M Six Months Ended June 30, 2026 —
      patients in the U.S. have been prescribed SUBLOCADE since launch 545,000 As of June 30, 2026 —
      People utilizing the FASTP physician locator 34,000 Q2 2026 —
      Share repurchases $175M Q2 2026 —
      SUBLOCADE Dispense Growth (YoY) 18% Q2 2026 —
      SUBLOCADE Net Revenue growth 21% Q2 2026 —
      SUBLOCADE share of U.S. LAI category 76% TTM Q2 2026 —
      Term loan repaid $333M 2026 —
      TTM SUBLOCADE Patients growth (YoY) 17% TTM Q2 2026 —
      U.S. SUBLOCADE net revenue $238M Q2 2026 —
      U.S. SUBLOCADE dispense unit volume growth 20% Q1 2026 —
      SUBLOCADE dispense unit volume growth 7% FY 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      INDV
      Indivior Pharmaceuticals, Inc.
      this stock
      		$4.61B +9.9% +4.3% 14.0 9.2%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $64.91B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $57.75B +15.8% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $50.24B +4.0% — — 0.0%
      HLN
      Haleon plc
      		 $43.41B -3.9% — — 0.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      334
      % held
      105.5%
      Net QoQ
      -3.6M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      298
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      10.9M
      Days to cover
      7.1d
      Change
      -399.3K sh
      View
      Short Volume
      Short vol %
      64%
      As of
      Aug 19, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      12.0K
      Value
      $481.4K
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      49.2%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$54.4K
      Buyers / Sellers
      1 / 0
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $1.2B
      Net income (FY)
      $210.0M
      EPS diluted
      $1.64
      View
      Buybacks
      Authorized
      $175.0M
      Remaining
      $100.0M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Aug 3, 2026
      This year
      17
      View
      Proposed Sales
      Value
      $764.6K
      Shares
      18.6K
      Filed
      Jul 10, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 3, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      INDV +2.6% -2.5% +17.3% -1.5% +9.9%
      SPY -0.4% +2.6% +10.7% +2.7% +12.5%
      vs SPY +3.0% -5.1% +6.5% -4.2% -2.7%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $175.00M
      Spent (derived)
      $75.00M
      Remaining
      $100.00M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1625297 CUSIP 45579U109 13F (30d) 311 filings 310 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)